Anaheim Bio Series A: Leiden-based biotech raises €40M to advance ANA-1, a small molecule for CPPD, into the clinic in 2027....
Anaheim Bio Series A: Leiden-based biotech raises €40M to advance ANA-1, a small molecule for CPPD, into the clinic in 2027....
Jazz closes its Actio Biosciences acquisition for $820M upfront and adds ABS-1230, an oral small molecule in development for KCNT1-related epilepsy....
BioMarin to acquire Alesta Therapeutics for $275M upfront, gaining ALE1 — a potential first oral therapy for hypophosphatasia (HPP)....
Vaderis raises an oversubscribed $152M Series B to fund engasertib through FDA approval, as Phase 3 HEROIC begins for rare disease HHT....
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M, adding ABS-1230, a first-in-class therapy for rare KCNT1+ epilepsy....
Unnatural Products Series B financing secures $45M after a Novartis pact to advance macrocycle drugs toward the clinic....
Vico Therapeutics begins twice-annual dosing of VO659 in HD, SCA3 & SCA1 patients. FDA IND cleared. First ASO targeting CAG repeat expansion across polyglutamine diseases....
“The preclinical progress of ALE1 and ALE2 underscores the company’s potential to deliver much-needed treatment options, and we are excited to support the continued advancement of these programs in 2025 and beyond.”...
“The preclinical progress of ALE1 and ALE2 underscores the company’s potential to deliver much-needed treatment options, and we are excited to support the continued advancement of these programs in 2025 and beyond.”...